S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ALRN

Aileron Therapeutics News Headlines

$0.66
-0.01 (-1.48%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.64
$0.71
50-Day Range
$0.66
$1.10
52-Week Range
$0.59
$2.33
Volume
404,944 shs
Average Volume
1.61 million shs
Market Capitalization
$60.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.57

Media Mentions By Week



Aileron Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALRN
News Sentiment

0.25

0.26

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALRN Articles
This Week

3

0

ALRN Articles
Average Week

Get Aileron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Aileron Therapeutics (NASDAQ:ALRN) News Headlines Today

SourceHeadline
MarketBeat logoAileron Therapeutics (NASDAQ:ALRN) Stock Rating Reaffirmed by Jonestrading
americanbankingnews.com - November 25 at 8:18 AM
MarketBeat logoAileron Therapeutics, Inc. to Post FY2022 Earnings of ($0.39) Per Share, William Blair Forecasts (NASDAQ:ALRN)
americanbankingnews.com - November 18 at 8:00 AM
MarketBeat logoAileron Therapeutics, Inc. (NASDAQ:ALRN) Expected to Earn FY2025 Earnings of ($0.67) Per Share
americanbankingnews.com - November 17 at 10:00 AM
MarketBeat logo-$0.08 Earnings Per Share Expected for Aileron Therapeutics, Inc. (NASDAQ:ALRN) This Quarter
americanbankingnews.com - November 17 at 9:12 AM
MarketBeat logoAileron Therapeutics (NASDAQ:ALRN) Posts Earnings Results, Hits Estimates
americanbankingnews.com - November 14 at 11:16 PM
MarketBeat logoAileron Therapeutics (NASDAQ:ALRN) Issues Earnings Results, Hits Expectations
americanbankingnews.com - November 13 at 1:44 PM
ca.finance.yahoo.com logoAileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
ca.finance.yahoo.com - November 12 at 9:35 AM
finance.yahoo.com logoAileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - November 12 at 9:35 AM
finance.yahoo.com logoAileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
finance.yahoo.com - October 7 at 9:41 AM
finance.yahoo.com logoAileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
finance.yahoo.com - September 30 at 6:08 PM
msn.com logoAileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent
msn.com - September 16 at 3:24 PM
finance.yahoo.com logoAileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
finance.yahoo.com - September 16 at 10:23 AM
finance.yahoo.com logoAileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
finance.yahoo.com - September 10 at 12:50 PM
finance.yahoo.com logoAileron Unveils Initial Data For Its Chemo Protective Agent
finance.yahoo.com - August 27 at 5:30 PM
finance.yahoo.com logoAileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
finance.yahoo.com - August 27 at 7:59 AM
finance.yahoo.com logoAileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - August 12 at 4:48 PM
nasdaq.com logoAileron Therapeutics, Inc. Common Stock (ALRN)
nasdaq.com - August 1 at 12:02 AM
finance.yahoo.com logoAileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
finance.yahoo.com - July 8 at 12:24 PM
finance.yahoo.com logoAileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings
finance.yahoo.com - July 1 at 7:20 PM
finance.yahoo.com logoAileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - July 1 at 9:16 AM
finance.yahoo.com logoHedge Funds Are Betting On Aileron Therapeutics, Inc. (ALRN)
finance.yahoo.com - June 30 at 12:52 PM
finance.yahoo.com logoAileron Therapeutics to be Added to the Russell Microcap® Index
finance.yahoo.com - June 24 at 8:04 AM
finance.yahoo.com logoAileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
finance.yahoo.com - May 19 at 7:57 AM
finance.yahoo.com logoAileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 6:17 PM
finance.yahoo.com logoAileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
finance.yahoo.com - March 24 at 7:25 PM
finance.yahoo.com logoAileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:52 PM
finance.yahoo.com logoAileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:52 PM
finance.yahoo.com logoAileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - March 2 at 7:42 AM
finance.yahoo.com logoAileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
finance.yahoo.com - January 11 at 9:33 AM
nasdaq.com logoAileron Announces $35.9 Mln Registered Direct Offering; Stock Down
nasdaq.com - January 6 at 3:17 PM
finance.yahoo.com logoAileron Therapeutics Announces $35.9 Million Registered Direct Offering
finance.yahoo.com - January 6 at 10:14 AM
baystreet.ca logoAileron Pops on Cusp of Cancer Drug Tests
baystreet.ca - January 5 at 2:38 PM
finance.yahoo.com logoMedicenna vs Aileron: Which Penny Stock Could Surge Over 200%?
finance.yahoo.com - December 23 at 7:10 AM
finance.yahoo.com logoAileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities
finance.yahoo.com - December 21 at 12:48 PM
finance.yahoo.com logoIs Aileron Therapeutics, Inc. (ALRN) A Good Stock To Buy?
finance.yahoo.com - November 29 at 9:50 PM
finance.yahoo.com logoNew Strong Sell Stocks for November 24th
finance.yahoo.com - November 24 at 10:17 AM
finance.yahoo.com logoAileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
finance.yahoo.com - November 12 at 7:44 PM
seekingalpha.com logoAileron Therapeutics reports positive proof-of-concept data from early-stage ALRN-6924 study in lung cancer
seekingalpha.com - October 26 at 11:31 AM
benzinga.com logoWhy Aileron's Stock Is Trading Lower Today
benzinga.com - October 26 at 11:31 AM
finance.yahoo.com logoAileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
finance.yahoo.com - October 24 at 9:43 AM
finance.yahoo.com logoAileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
finance.yahoo.com - October 20 at 11:09 AM
nasdaq.com logoAileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher
nasdaq.com - October 13 at 5:26 PM
seekingalpha.com logoAileron to announce PoC data from early-stage study with chemoprotection agent
seekingalpha.com - October 12 at 3:50 PM
markets.businessinsider.com logoAileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
markets.businessinsider.com - October 12 at 9:07 AM
in.finance.yahoo.com logoAileron Therapeutics, Inc. (015.F)
in.finance.yahoo.com - October 8 at 1:27 PM
seekingalpha.com logoAileron Therapeutics inks $15M stock purchase deal with Lincoln Park Capital
seekingalpha.com - September 22 at 1:06 AM
finance.yahoo.com logoAileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
finance.yahoo.com - September 21 at 8:05 PM
finance.yahoo.com logoAileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
finance.yahoo.com - September 10 at 11:16 AM
benzinga.com logoThinking about buying stock in Beam Therapeutics, Digital Turbine, Arbutus Biopharma, Aileron Therapeutics, or Snap Inc?
benzinga.com - August 8 at 7:35 AM
marketwatch.com logoTop Penny Stocks To Watch Under $2 This Week
marketwatch.com - August 5 at 11:06 PM
Get Aileron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.